Compounds > framycetin
Page last updated: 2024-08-18

framycetin and pravastatin

framycetin has been researched along with pravastatin in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19901 (14.29)18.7374
1990's1 (14.29)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Campillo, NE; Guerra, A; Páez, JA1
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Brown, WV; Karmally, W; Smith, DA1
Vanhanen, H1
Hayden, MR; Mujumdar, VS; Tyagi, SC1

Other Studies

7 other study(ies) available for framycetin and pravastatin

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:3

    Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical

2010
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:1

    Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics

2011
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Treating hyperlipidemia, Part III: Drug therapy.
    Geriatrics, 1987, Volume: 42, Issue:8

    Topics: Aged; Enzyme Inhibitors; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Pravastatin

1987
Cholesterol malabsorption caused by sitostanol ester feeding and neomycin in pravastatin-treated hypercholesterolaemic patients.
    European journal of clinical pharmacology, 1994, Volume: 47, Issue:2

    Topics: Anticholesteremic Agents; Cholesterol; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intestinal Absorption; Male; Middle Aged; Neomycin; Pravastatin; Sitosterols

1994
Homocyst(e)ine induces calcium second messenger in vascular smooth muscle cells.
    Journal of cellular physiology, 2000, Volume: 183, Issue:1

    Topics: Angiotensin II; Animals; Aorta; Calcium; Cells, Cultured; Collagen; Felodipine; Fluorescent Dyes; Fura-2; Glutathione; Homocysteine; Homocystine; Kinetics; Muscle, Smooth, Vascular; Neomycin; NG-Nitroarginine Methyl Ester; Pravastatin; Rats; Second Messenger Systems; Staurosporine; Tetradecanoylphorbol Acetate; Thapsigargin

2000